Use access key #2 to skip to page content.
$0.28 -0.01 (-3.79%)
10/10/2008 3:55 PM

ENTREMED, INC. (ENMD)

CAPS Rating:
*

A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

ENMD doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

45 Outperforms
15 Underperforms
 

All-Stars

7 Outperforms
11 Underperforms
 

Members bullish on ENMD are also bullish on:

Members bearish on ENMD are also bearish on:

Ticker Tags

Micro Cap (4824), Biotechnology (295)
Suggest a tag

ENTREMED, INC. At A Glance

Current Price: $0.28
Last Trade Time: 10/10/2008 3:55 PM
Open: $0.26
Previous Close: $0.29
Daily Range: $0.25 - $0.30
52-Week Range: $0.25 - $1.70
Volume: 256,140
Market Cap: $25.70M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

ENMD VS S&P 500 (SPY)

ENMD 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for ENMD

More Headlines...

Top Bull Pitch

Recs

2

ENTREMED, INC. (ENMD)

Avatar garupix (20.76) Submitted: 2/06/07 1:09 PM

Antiangiogenisis is a credible approach to treating cancerous tumors and ENMD pipeline drugs are performing well in Phase II clinical trials.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

ENTREMED, INC. (ENMD)

Avatar amteague777 (83.05) Submitted: 6/01/07 6:27 PM

Underperformed s&p since 1996 except for blip in 2000. Negative net income 2004-2007. Currently negative cash flow, ROE, ROA.

Replies: 1 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 13 :   1 2 3 Next »

Show Pitch Replies

Recs

1

 (ENMD)

Avatar amteague777 (83.05) Submitted: 6/01/07 6:27 PM : Underperform Start Price: $1.90 ENMD Score: 42.96

Underperformed s&p since 1996 except for blip in 2000. Negative net income 2004-2007. Currently negative cash flow, ROE, ROA.

Report this Post Replies: 1 | Reply | Permalink

Recs

0

 (ENMD)

Avatar dwr53 (< 20) Submitted: 4/25/07 8:28 PM : Outperform Start Price: $1.79 ENMD Score: -43.61

They have several phase two cancer candidates. Approximately 25% of the shares are owned by Celgene. I suspect they will be taken out by a big pharma looking to improve their pipeline.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (ENMD)

Avatar jilbear (30.11) Submitted: 4/15/07 10:50 AM : Underperform Start Price: $1.78 ENMD Score: 45.82

This company can only go down from the information available. They are eating cash. This is coming off their second stock offering. It will be years until any of their medications ever hit the market. The bottom line is, this company wont be profitable for at least another 3 years, and I dont think it can stick it out without exhausting its cash supply.

Report this Post Replies: 0 | Reply | Permalink

Recs

2

 (ENMD)

Avatar garupix (20.76) Submitted: 2/06/07 1:09 PM : Outperform Start Price: $1.65 ENMD Score: -44.30

Antiangiogenisis is a credible approach to treating cancerous tumors and ENMD pipeline drugs are performing well in Phase II clinical trials.

Report this Post Replies: 0 | Reply | Permalink

Recs

2

 (ENMD)

Avatar hlacheen (97.48) Submitted: 12/21/06 9:39 PM : Underperform Start Price: $1.69 ENMD Score: 45.97

Just look at the income statement and cash flow.... this company is a cash-burning disaster, it is NOT worth $120m

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 13 :   1 2 3 Next »

Wall Street

There are no Wall Street tracker picks.

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners